Ian Read, Pfizer’s CEO, gets pay increase to $27.9 million—a 61% pay increase

Ian Read, the CEO of drug giant Pfizer Inc., has seen his compensation raised by 61 percent, according to finance filings reported by Bloomberg. This comes after the drug company hiked prices of dozens of drugs in 2017.

Pfizer’s board reportedly approved the pay raise for Read because they saw it as a “compelling inventive” to keep the CEO from retiring. Mind you, he’s turning 65 in May, so he can technically choose to go at any time. Part of the deal is that Read must stay on at least through next March and is barred from working with a competitor for a minimum of two years after that.

Per Bloomberg, Read’s compensation included in part a salary of $1.96 million, bonus of $2.6 million, $13.1 million in equity awards that are linked to financial goals and stock price, and $8 million in special equity award that will vest if the company’s stock return goes above 25 percent for 30 consecutive trading days before end of the year 2022. To compare, Read’s compensation was at $17.3 million in 2016.

Hamza Khalid

Hamza Khalid is the Lead Editor at The Jolt Journal. You're more than welcome to follow him on Twitter and follow The Jolt Journal on Twitter and Facebook. If you have any questions, concerns, or need to report something in this article, please send our team an email at [email protected]. This story may be updated at any time if new information surfaces.

At The Jolt Journal, no one tells us what to write or how to write it. This is why, in the era of lies and bias, readers turn to an independent source. Rest assured, all information on our website is free of any bias or influence. If you see anything wrong with a story, please don't hesitate to reach out. We do our very best to report on the latest available information.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.